D9Z Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue expanded substantially across the annual periods, while TTM growth remains positive. This multi-year expansion indicates continued demand for Clinica Baviera’s ophthalmology services and provides a durable base for reinvestment and operating scale.
Strong ProfitabilityConsistently strong net margins and solid operating profitability show that the clinic network converts revenue into earnings effectively. Sustained profitability can support internal funding, strengthen resilience, and provide capacity to invest in future service growth.
Improved Balance Sheet And Cash GenerationMaterial deleveraging combined with operating cash flow above net income strengthens financial flexibility and earnings quality. Lower debt should reduce balance-sheet pressure, while internally generated cash can support investment and other capital allocation needs.
Bears Say
Recent Margin VolatilityRecent movement in gross and operating margins creates uncertainty about how durable the company’s profitability profile is. If the changes reflect mix, pricing, or cost pressure, continued earnings growth may not translate into stable operating returns.
Moderate Free-Cash-Flow ConversionAlthough free cash flow is positive and improving, only moderate conversion from reported earnings suggests that reinvestment needs or working-capital movements absorb part of the profit. This can limit the cash available for expansion and capital returns.
Deleveraging Durability Requires ConfirmationThe current balance sheet is much stronger, but the company previously carried materially higher leverage. That history means investors should verify that the improvement is structural rather than timing-related, because any reversal could reduce financial flexibility.
Clinica Baviera News
D9Z FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Currently, no data Available
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is CHF806.62M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Jul 29, 2026. The company reported $0.69 earnings per share for the quarter.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Undervalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA does not currently pay dividends.
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of $0.69 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in CH:D9Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditions. Its facilities offer a wide range of specialized services, addressing issues such as myopia, hyperopia, astigmatism, presbyopia, cataracts, retinal disorders, pediatric eye ailments, glaucoma, strabismus (squint), corneal diseases, neuro-ophthalmology, lacrimal duct problems (vías lagrimales), and oculoplastic procedures. The corporate headquarters are located in Madrid, Spain.
D9Z Stock 12 Month Forecast
Average Price Target
$66.09